ArticleArchives of microbiology2026
Modulation of experimental colitis by Enterococcus faecalis, Enterococcus faecium, and Bacillus subtilis: insights from infectious and chemical models.
Article in Archives of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The roles of Enterococcus faecium (E. faecium), Enterococcus faecalis (E. faecalis), and Bacillus subtilis (B. subtilis) in colitis remain poorly defined, with existing literature presenting inconsistent and often contradictory evidence. This study aimed to elucidate their contributions to inflammatory bowel disease (IBD) using both infectious (non-typhoidal Salmonella enterica serovar Typhimurium, S. typhimurium) and chemical (dextran sulfate sodium, DSS)-induced colitis models. Colitis was induced in C57BL/6 mice via a single oral dose of S. typhimurium (ATCC14028) and/or administration of DSS for seven days. E. faecium (ATCC51559), E. faecalis (ATCC700802), and B. subtilis (MTCC25292) were orally administered. Disease progression was assessed through body weight monitoring, disease activity index (DAI), biochemical assays, and histopathological evaluation of colon tissues. Administration of individual E. faecium strain or E. faecalis strain did not significantly alter disease parameters. However, administered strain of E. faecalis exacerbated colitis severity in the S. typhimurium-induced model. Co-administration of DSS with S. typhimurium resulted in a pronounced aggravation of disease severity, as evidenced by clinical, biochemical, and histological markers. Notably, treatment with B. subtilis showed colitis attenuation, demonstrated by improvements in DAI, colon length, fecal calprotectin levels, and histopathological scores. These disease-modifying effects were associated with decreased colonic expression of pro-inflammatory mediators (CXCL-1, TNF-α, IL-1β) and increased levels of the anti-inflammatory cytokine IL-10. Tested strain of E. faecalis does not induce colitis under steady-state conditions in this model but may aggravate pathogen-induced colitis, whereas E. faecium strain shows no significant effect under the applied experimental conditions. Combined DSS and S. typhimurium exposure induces robust colitis, wherein B. subtilis exhibits potential disease-modifying effect.
Indexed as
Identifiers
42566044What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.